Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials
Novus said the results from single-dose phase 1 studies met theprimary objectives and demonstrated a favorable safety and tolerabilityprofile
Read more
news
KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors
Daniel Soland has been appointed to Kalvista Board of Directors .
Read more
Aura Biosciences to Present Two Year Phase 1b/2 Clinical Data for AU-011 at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting
Aura Biosciences’ lead productcandidate for the primary treatment of primary choroidal melanoma, willbe highlighted in a poster presentation at the Association for Researchin Vision and Ophthalmology (ARVO) 2019 Annual Meeting
Read more
CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)
BELRAPZO is indicated for the treatment of patients with indolent B-cellnon-Hodgkin lymphoma (NHL) that has progressed during or within sixmonths of treatment with rituximab or a rituximab-containing regimen.
Read more
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
many patients with advancedrenal cell carcinoma need additional treatment options that can helpimprove survival outcomes
Read moreAscellaHealth Supports DEA’s National Prescription Drug Take Back Day, Points to SafeUseNow℠ Solution to Combat Spread of Prescription Drug Abuse
BERWYN, Pa.–(BUSINESS WIRE)–In recognition of the Drug Enforcement Administration’s (DEA) National Prescription Drug Take Back Day, April 27, 2019, AscellaHealth
Read more
Susmed: Demonstration of Clinical Data Managing System Using Blockchain Technology
In this pilot project, the Susmed system uses blockchain technology, which isexpected to be more cost-effective than conventional methods inmonitoring of clinical researches and ensuring data accuracy duringmonitoring.
Read more
FSD Pharma Receives Cannabis Sales License from Health Canada
The license allows the current FSD facility to supply and sell cannabisproducts. The company expects receiving the amended sales licensethat will include the sale of dried and fresh cannabis flower in thenear future.
Read more
Global Anticoagulants Reversal Drugs Market Covering Key Players & Their Competitive Strategies, 2019: Analysis & Outlook Through 2018-2026 – ResearchAndMarkets.com
The global anticoagulants reversal drugs market expected to expand at aCAGR of 15.3% from 2018 to 2026, owing to the approval of blockbusterdrugs in recent years and strong pipeline driving the market.
Read moreAnterior Uveitis – Pipeline Insight, 2019 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Anterior Uveitis – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. The report offers comprehensive
Read more